Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors

PURPOSE: The hedgehog (Hh) signaling pathway, a key regulator of cell growth and differentiation during development is implicated in pathogenesis of certain cancers. Vismodegib (GDC-0449) is a small-molecule inhibitor of smoothened, a key component of Hh signaling. This phase I trial assessed GDC-04...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Cancer Res
Autori principali: LoRusso, Patricia M., Rudin, Charles M., Reddy, Josina C., Tibes, Raoul, Weiss, Glen J., Borad, Mitesh J., Hann, Christine L., Brahmer, Julie R., Chang, Ilsung, Darbonne, Walter C., Graham, Richard A., Zerivitz, Kenn L., Low, Jennifer A., Von Hoff, Daniel D.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2011
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5244484/
https://ncbi.nlm.nih.gov/pubmed/21300762
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-2745
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi